KarMMa-3: A phase 3 study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy vs standard regimens in relapsed and refractory multiple myeloma Meeting Abstract
| Authors: | Delforge, M.; Baz, R. C.; Cavo, M.; Callander, N. S.; Ghobadi, A.; Rodriguez-Otero, P.; Mateos, M. V.; Massaro, M.; Ding, L.; Patel, P.; Pittari, G.; Novick, S.; Giralt, S. A.; Berdeja, J. G. |
| Abstract Title: | KarMMa-3: A phase 3 study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy vs standard regimens in relapsed and refractory multiple myeloma |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547202223 |
| DOI: | 10.1182/blood-2020-137156 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 24 -- Source: Wos |
